10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Cytomegalovirus (CMV) seropositivity and anti-CMV immunoglobulin G (IgG) levels are associated with adverse health outcomes in elderly populations. Among people living with human immunodeficiency virus (PLWH), CMV seropositivity has been associated with persistent CD8 T-cell elevation and increased risk of developing non-AIDS comorbidities despite long-term antiretroviral therapy (ART). Herein, we investigated whether CMV seropositivity and elevation of anti-CMV IgG levels were associated with increased epithelial gut damage, microbial translocation, and systemic inflammation.

          Methods

          A total of 150 PLWH (79 ART-naive and 71 ART-treated) were compared to 26 without human immunodeficiency virus (HIV) infection (uninfected controls). Plasma markers of HIV disease progression, epithelial gut damage, microbial translocation, nonspecific B-cell activation, anti-CMV and anti–Epstein-Barr virus (EBV) IgG levels, and proinflammatory cytokines were measured.

          Results

          CMV seropositivity and elevated anti-CMV IgG levels were associated with markers of epithelial gut damage, microbial translocation, and inflammation in PLWH and participants without HIV infection. In contrast, total nonspecific IgG, immunoglobulin M, immunoglobulin A, and anti-EBV IgG levels were not associated with these markers. CMV seropositivity was associated with markers of epithelial gut damage, microbial translocation, and inflammation independent of sociodemographic and behavioral characteristics of the study population.

          Conclusions

          CMV-seropositive people with and without HIV had increased epithelial gut damage, microbial translocation, and inflammation. Furthermore, anti-CMV IgG levels were independently associated with increased epithelial gut damage and microbial translocation. CMV coinfection may partially explain persistent gut damage, microbial translocation, and inflammation in ART-treated PLWH.

          Abstract

          Cytomegalovirus (CMV) seropositivity and anti-CMV immunoglobulin G levels are associated with increased epithelial gut damage, microbial translocation, and inflammation in antiretroviral therapy (ART)–naive and ART-treated people living with human immunodeficiency virus and uninfected controls.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.

          Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and expert opinion-based consensus guidelines on CMV management including prevention, treatment, diagnostics, immunology, drug resistance, and pediatric issues. Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease. The following report summarizes the updated recommendations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis

            Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes primary infection, reinfection, or reactivation because these three types of infection are all controlled by the normal immune system. However, CMV becomes an important pathogen in individuals whose immune system is immature or compromised, such as the unborn child. Several vaccines against CMV are currently in clinical trials that aim to induce immunity in seronegative individuals and/or to boost the immunity of those with prior natural infection (seropositives). To facilitate estimation of the burden of disease and the need for vaccines that induce de novo immune responses or that boost pre-existing immunity to CMV, we conducted a systematic survey of the published literature to describe the global seroprevalence of CMV IgG antibodies. We estimated a global CMV seroprevalence of 83% (95%UI: 78-88) in the general population, 86% (95%UI: 83-89) in women of childbearing age, and 86% (95%UI: 82-89) in donors of blood or organs. For each of these three groups, the highest seroprevalence was seen in the World Health Organisation (WHO) Eastern Mediterranean region 90% (95%UI: 85-94) and the lowest in WHO European region 66% (95%UI: 56-74). These estimates of the worldwide CMV distribution will help develop national and regional burden of disease models and inform future vaccine development efforts.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              HIV-associated chronic immune activation.

              Systemic chronic immune activation is considered today as the driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS). A residual chronic immune activation persists even in HIV-infected patients in which viral replication is successfully inhibited by anti-retroviral therapy, with the extent of this residual immune activation being associated with CD4(+) T-cell loss. Unfortunately, the causal link between chronic immune activation and CD4(+) T-cell loss has not been formally established. This article provides first a brief historical overview on how the perception of the causative role of immune activation has changed over the years and lists the different kinds of immune activation characteristic of human immunodeficiency virus (HIV) infection. The mechanisms proposed to explain the chronic immune activation are multiple and are enumerated here, as well as the mechanisms proposed on how chronic immune activation could lead to AIDS. In addition, we summarize the lessons learned from natural hosts that know how to 'show AIDS the door', and discuss how these studies informed the design of novel immune modulatory interventions that are currently being tested. Finally, we review the current approaches aimed at targeting chronic immune activation and evoke future perspectives. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
                Bookmark

                Author and article information

                Journal
                Clin Infect Dis
                Clin. Infect. Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                15 September 2020
                14 October 2019
                14 October 2019
                : 71
                : 6
                : 1438-1446
                Affiliations
                [1 ] Chronic Viral Illness Service, McGill University Health Centre , Montreal, Quebec, Canada
                [2 ] Infectious Diseases and Immunity in Global Health Program, Research Institute, McGill University Health Centre , Montreal, Quebec, Canada
                [3 ] Department of Microbiology and Immunology, McGill University , Montreal, Quebec, Canada
                [4 ] Chongqing Public Health Medical Center , Chongqing, China
                [5 ] Centre de Recherche du Centre Hospitalier de l’Université de Montréal , Montréal, Quebec, Canada
                [6 ] Associates of Cape Cod Inc , Falmouth, Massachusetts, USA
                [7 ] Department of Family Medicine, McGill University , Montreal, Quebec, Canada
                [8 ] Department of Microbiology-Immunology and Infectious Diseases, Laval University , Quebec City, Quebec, Canada
                [9 ] Division of Hematology, McGill University Health Centre , Montreal, Quebec, Canada
                Author notes
                Correspondence: J.-P. Routy, McGill University, Research Institute of McGill University Health Centre, Glen site, 1001 Boulevard Décarie, EM 3-3232, Montreal, QC, H4A 3J1, Canada ( jean-pierre.routy@ 123456mcgill.ca ).
                Article
                ciz1001
                10.1093/cid/ciz1001
                7486843
                31608409
                9ab94faa-52e4-454b-9e0c-dc8576002f61
                © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 06 August 2019
                : 07 October 2019
                : 26 September 2019
                : 02 December 2019
                Page count
                Pages: 11
                Funding
                Funded by: Fonds de la Recherche Québec-Santé;
                Funded by: Réseau de bioimagerie du Québec;
                Funded by: Canadian Institutes of Health Research, DOI 10.13039/501100000024;
                Award ID: MOP 103230
                Award ID: PTJ 166049
                Funded by: Canadian HIV Trials Network, Canadian Institutes of Health Research, DOI 10.13039/501100002879;
                Award ID: CTN 257
                Funded by: National Institutes of Health, DOI 10.13039/100000002;
                Funded by: Canadian Foundation for AIDS Research, DOI 10.13039/100008220;
                Award ID: 02-512
                Categories
                Articles and Commentaries
                AcademicSubjects/MED00290

                Infectious disease & Microbiology
                hiv,cytomegalovirus,epithelial gut damage,microbial translocation,inflammation

                Comments

                Comment on this article